anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a new treating agent for fibromyalgia.  <P>SOLUTION: Since the etiology and onset mechanism of the fibromyalgia are not elucidated yet, the fibromyalgia is a difficult disease for developing its treating drug. For the fibromyalgia, the administration of an antidepressant is reported to show a certain effectiveness, but there is a tendency that it is difficult to remove pain accompanying with the disease completely. By administering fluvoxamine maleate which is an antidepressant, to a patient of the fibromyalgia, the improvement or disappearance of the pain is observed. Although the improvement of the symptoms is not observed by the administration of the other antidepressants, the improvement of the symptoms is observed in some cases by the administration of the fluvoxamine maleate. Since the fluvoxamine maleate is a serotonin reuptake inhibitor, there is a possibility that the fluvoxamine maleate is associated with the onset mechanism of the fibromyalgia.  <P>COPYRIGHT: (C)2009,JPO&INPIT
This is a randomized (individuals assigned to study treatment by chance), open-label (identity of assigned study drug will be known) study designed to evaluate the efficacy and safety of ibrutinib versus rituximab in adult Asia Pacific region patients with relapsed/refractory CLL or SLL with active disease requiring treatment who have failed at least 1 prior line of therapy and are not considered appropriate candidates for treatment or retreatment with purine analog-based therapy. Approximately 150 patients will be randomly assigned in a 1:2 ratio into 2 treatment arms to receive either intravenous rituximab (Treatment Arm A) for 6 cycles or oral ibrutinib (Treatment Arm B) until disease progression or unacceptable toxicity, whichever occurs first. The study will include screening, treatment, and follow-up phases. Treatment will extend from randomization until study drug discontinuation. Follow-up will consist of 2 phases: post-treatment (from the discontinuation of treatment for reasons other than disease progression until the patient has progressive disease) and post-disease progression (subsequent anticancer therapy and survival status will be recorded until death, lost to follow-up, consent withdrawal, or study closure). Patients in the rituximab arm with disease progression or who meet the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria for requiring subsequent anti-CLL therapy may be considered for cross over to receive ibrutinib 420 mg orally, daily until disease progression, unacceptable toxicity, withdrawal from study, or until study end whichever occurs earliest. Efficacy evaluations will assess for disease response and progression in accordance with International Workshop on Chronic Lymphocytic Leukemia 2008 criteria. Serial pharmacokinetic (study of what a drug does to the body) blood samples will be collected in the ibrutinib treatment group. Safety will be assessed throughout the study.
Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893.
Information is automatically shared among a plurality of remote/mobile data processing nodes which are temporarily and intermittently linked to a data processing server by distributing an information form to users corresponding to first remote/mobile nodes. A user may complete the form to create an instance of the form and define an instance distribution to users corresponding to the distribution list. The instance is automatically distributed to users corresponding to the distribution list. As owner of the form, the user may also modify the form, and these modifications are also automatically distributed to the users at the third node. A second form may be linked to the form and automatically distributed to the third nodes as well. When distributing a file to a node, any other files which are required are also automatically distributed.
Popliteal entrapment syndrome (PES) describes a cluster of symptoms related to the compression of the neurovascular bundle in the popliteal fossa, most commonly involving the popliteal artery. In approximately 10-15% of the cases of popliteal entrapment syndrome, the popliteal vein is compressed. Symptoms of popliteal vein entrapment can mimic venous insufficiency or deep venous thrombosis, causing the diagnosis to be missed or delayed. Diagnosis of popliteal vein entrapment can be done with duplex imaging with flexion and extension maneuvers; however, venography is the gold standard for diagnosis. While popliteal vein entrapment is commonly associated with younger individuals, it may also be an underdiagnosed condition in older patients. We describe two cases of successful diagnosis and treatment of late-onset presentation of popliteal vein entrapment.
Vaccination of Melanoma Patients Using DCs Loaded with Allogeneic Melanoma Extracts.

In Chile, this study constitutes the first phase I clinical trial for treating advanced malignant melanoma using dendritic cell vaccines loaded with allogeneic tumor extracts complemented or not with low doses of rIL-2. Since chemotherapy and radiotherapy only offer palliative effects in advanced melanoma, resulting in an inferior prognosis for these patients, the trial intends to develop a protocol that would adapt to the reality of Chile, allowing for a combination of high technology and low costs.

After obtaining approval from the human research ethics committee from Universidad de Chile, 86 patients will be recruited who will be duly informed about the scope of these protocols and the realistic prospects of success. The participants then will undergo a comprehensive health check to assess their overall health. The participants will undergo a leukapheresis at the blood bank of the Clinical Hospital of the University de Chile. Peripheral blood mononuclear cells (PBMCs) will be separated using a Ficoll-Hypaque gradient in the laboratory of Antitumor Immunology at the Institute of Biomedical Sciences, Faculty of Medicine of the University de Chile. Some of the cells will be cryopreserved in liquid nitrogen for future use. Approximately 1.8x108 PBMCs will be placed in 6-well culture plates and incubated at 37°C and 7% CO2 for two hours. The suspended cells, peripheral blood lymphocytes (PBLs), will be removed and frozen for later use. The monocytes adhering to the plastic will be incubated for seven days in a serum-free culture medium (AIM-V therapeutic, GIBCO, BRL) in the presence of 500 U/ml of IL-4 and 800 U/ml of GM-CSF. On the sixth day, the DCs will be pulsed with tumor extracts from allogeneic melanoma cell lines, previously checked for sterility, and incubated for 6 hours at 37°C and 7% CO2, followed by maturation stimulus with TNF-alpha for 12 to 18 hours. Mature DCs will be characterized by flow cytometry. Approximately 10 to 20 x 106 pulsed DCs will be subcutaneously injected. This routine will be repeated weekly for at least four times and a maximum of 6 times. After the fourth dose, the participant's general condition, possible clinical regressions, adverse side effects, and the effects of the treatment on the immune system will be evaluated. This evaluation will be done through in vivo delayed-type hypersensitivity (DTH) assays using melanoma extracts and their respective controls. Planned in vitro assays for immune response measuring will include the detection of anti-melanoma CTL precursors by ELISPOT, cytokine production, proliferation assays, and quantifying the CD4/CD8 ratio by flow cytometry.
1,196,678. Contraceptive devices. CHEMOLIMPEX MAGYAR VEGYIARU KULKERESKEDELMI VALLALAT. 21 Nov., 1967 [24 April, 1967], No. 53005/67. Heading ASR. [Also in Division C3] A water-soluble contraceptive and antivenereal device comprises a film. or moulded article of water-soluble polyvinyl alcohol in admixture with and/or coated with a water-soluble spermicide, the film being a discrete piece of a size suitable for introduction into the vagina. The spermicide may comprise cetylpyridinium, bromide, nonylphenoxypolyethoxyethanol, triisopropylphenoxypolyethoxyethanol, hexylresorcinal, or pherylmercuric acetate. The device may comprise a piece of polyvinyl alcohol film material 4 x 4 cm. impregnated and coated with cetylpyridinium bromide and used as a vagical suppository and the cetylpyridinium bromide used for the impregnation may be in an aqueous solution of polyvinyl alcohol. The device may alternatively comprise a cap-shaped member 3-4 cm. diameter and 2 cm. height moulded from polyvinyl alcohol material containing the spermicide.
The present invention relates to, inter alia, methods for inhibiting the interaction of the B-lymphocyte antigen, B7-2, with its natural ligand on the surface of an immune cell are disclosed. The methods comprise contacting the immune cell with an agent which inhibits B7-2 binding with its natural ligand, to thereby inhibit the interaction. Examples of such agents are provided, and include a soluble form of B7-2, an antibody that recognized B7-2. The method may also include contacting the immune cell with an agent that blocks the interaction of B7-1 with its natural ligand. Further, the method may include contacting the immune cell with an immunomodulating agent, for example, an antibody reactive with CD28, an antibody reactive with CTLA4, an antibody reactive with a cytokine, a CTLA4Ig fusion protein, a CD28Ig fusion protein, and an immunosuppressive drug. Both in vivo and in vitro applications of the method are disclosed.
In 2020, the Olympic Refuge Foundation (ORF) initiated Game Connect, a sport-for-protection project in Uganda. The current study lasted from September 2022 to August 2023. The project was executed by a consortium led by non-governmental organizations including AVSI Foundation, Right to Play, Youth Sport Uganda, the Uganda Olympic Committee, and the United Nations High Commissioner for Refugees. Included districts were Kampala, Rwamwanja, Palabek, Adjumani, and Kyangwali as they host the largest refugee settlements. Also the surrounding host communities were included. A total of 1,912 potential villages that could be targeted were identified, some of which were grouped in clusters. The decision to cluster villages was influenced by factors such as the limited number of young people in some villages and proximity of households to each other despite living in different villages. In total, 869 villages out of the 1,912 were at random selected for inclusion in the program. Block randomization was applied to ensure equal representation across the targeted districts. Following selection of the villages, all youth in selected villages were identified. Eligible participants in the selected 869 villages of the five catchment areas were: (a) young displaced or host-community adolescents and young adults aged 15 to 24 years, and (b) at least mild symptoms of anxiety and/ or depression, defined as a Patient Health Questionnaire -9, adolescent version (PHQ-9-A) (Spitzer et al., 1999) and / or the Generalized Anxiety Disorder-7 (GAD-7) (Spitzer et al., 2006) score of 5 or higher. Those with severe depression (PHQ-9-A≥20) and / or anxiety (GAD-7≥15) were eligible to participate, but additionally referred to local services for specialized support. Eligible young people were at random allocated to either 12 weeks of physical activity or to 12 weeks in a waiting control condition. All participants completed at baseline and immediately post-intervention the interviewer-administered PHQ-9-A (Spitzer et al., 1999) and GAD-7 (Spitzer et al., 2006). An independent team of well-trained research assistants performed the interviews to minimize potential bias. The research assistants were recruited locally from refugee settlements and surrounding host communities. Data collection tools were pretested to ensure coherence and understandability of questions before the actual data collection commenced. Ethical approval was obtained from the Makerere University School of Social Sciences Research Ethics Committee and the Uganda National Council for Science and Technology. Informed written assent was obtained from all participants. Consent was secured from the current caregivers of youths aged 15-17 years.
Insulin resistance is a positive protective reaction against surgery . As a response to surgery, activation of neuroendocrine and inflammation systems occurs as a protective reaction. However, this resistance has some negative consequences for patient health. It is associated with infectious complications. At the same time, Postoperative insulin resistance has been shown to correlate with the length of postoperative stay in hospital. Recently several clinical studies have shown that a carbohydrate-rich drink given 2 h before surgery diminishes postoperative insulin resistance in patient. The aim of our study is to investigate the influence on insulin resistance in patient with diabetes.
BACKGROUND: In patients affected by high-risk nonmuscle invasive bladder cancer (HR-NMIBC) progression to muscle invasive status is considered as the main indicator of local treatment failure. We aimed to investigate the effect of progression and time to progression on overall survival (OS) and to investigate their validity as surrogate endpoints.
METHODS: A total of 1,510 patients from 18 different institutions treated for T1 high grade NMIBC, followed by a secondary transurethral resection and BCG intravesical instillation. We relied on random survival forest (RSF) to rank covariates based on OS prediction. Cox's regression models were used to quantify the effect of covariates on mortality.
RESULTS: During a median follow-up of 49.0 months, 485 (32.1%) patients progressed to MIBC, while 163 (10.8%) patients died. The median time to progression was 82 (95%CI: 78.0-93.0) months. In RSF time-to-progression and age were the most predictive covariates of OS. The survival tree defined 5 groups of risk. In multivariable Cox's regression models accounting for progression status as time-dependent covariate, shorter time to progression (as continuous covariate) was associated with longer OS (HR: 9.0, 95%CI: 3.0-6.7; P < 0.001). Virtually same results after time to progression stratification (time to progression ≥10.5 months as reference).
CONCLUSION: Time to progression is the main predictor of OS in patients with high risk NMIBC treated with BCG and might be considered a coprimary endpoint. In addition, models including time to progression could be considered for patients' stratification in clinical practice and at the time of clinical trials design.
Estrogen receptor α (ERα) plays a crucial role in regulating glucose and energy homeostasis during type 2 diabetes mellitus (T2DM). However, the underlying mechanisms remain incompletely understood. Here we find a ligand-independent effect of ERα on the regulation of glucose homeostasis. Deficiency of ERα in the liver impairs glucose homeostasis in male, female, and ovariectomized (OVX) female mice. Mechanistic studies reveal that ERα promotes hepatic insulin sensitivity by suppressing ubiquitination-induced IRS1 degradation. The ERα 1-280 domain mediates the ligand-independent effect of ERα on insulin sensitivity. Furthermore, we identify a peptide based on ERα 1-280 domain and find that ERα-derived peptide increases IRS1 stability and enhances insulin sensitivity. Importantly, administration of ERα-derived peptide into obese mice significantly improves glucose homeostasis and serum lipid profiles. These findings pave the way for the therapeutic intervention of T2DM by targeting the ligand-independent effect of ERα and indicate that ERα-derived peptide is a potential insulin sensitizer for the treatment of T2DM.
A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a modified Ambu Spur II bag valve mask.
Large cell calcifying Sertoli cell tumors (LCCSCTs) are rare testicular tumors, representing <1 % of all testicular neoplasms. Almost 40 % of patients with LCCSCTs will present in the context of the inherited tumor predisposition syndrome, the Carney complex. While most LCCSCTs are benign, 10-20 % have malignant behavior. The aim of our study was to analyze LCCSCTs for novel molecular alterations in addition to PRKAR1A mutations and to identify potential drivers for malignant progression. Eight LCCSCTs diagnosed at two institutions were included. Two patients had the Carney complex confirmed on subsequent genetic testing, and two tumors had several adverse pathological findings. One patient presented with metastatic disease at the time of initial diagnosis. Targeted next-generation sequencing detected PRKAR1A alterations in all cases, with heterozygous PRKAR1A mutations in 5 tumors, germline Carney-complex-associated PRKAR1A mutation in 2 patients, and PRKAR1A fusion in 1 tumor. Additionally, sequencing the metastatic case identified CDKN1B and TERT promoter gene mutations. All tumors showed a low tumoral mutational burden and unremarkable copy number alterations except for frequent LOH of 17q24 encompassing the PRKAR1A locus. RNA expression analysis showed increased expression of several markers including novel PRUNE2, and usual markers like inhibin and calretinin. Our study showed that while LCCSCTs have been reported in the setting of cancer predisposition syndromes, the majority of these tumors occur sporadically. PRKAR1A alterations were present in all cases and appear to be the major driver in LCCSCTs. It remains to be determined whether malignant progression may be caused by additional driver mutations.
Feature-based clinical interpretation of whole exome and transcriptome data for precision cancer medicine is provided. In various embodiments, genomic data of a subject is received. The genomic data comprises somatic mutations. A plurality of features is determined from the genomic data of the subject. A similarity metric is determined between the plurality of features and each of a plurality of reference genomes. One or more potentially actionable feature is determined from the similarity.
The revulsive massage cream, according to the utility model, has a powerful effect on skin receptors and influences not only the cells of the epidermis but also has a relaxing effect on the body. It is fully resorbed, stays for a long time on the treated area, allows for performing a quality massage – provides a lubricous effect during the massage, improves the elasticity and plasticity of the skin, prevents the local stretching of the skin during the massage. It is suitable as a supplementary product in the comprehensive treatment of arthralgias, myalgias, neuralgias, and neuritis, headache, colds, bruises, and for providing an analgesic effect when administered alone. It can also be used in sports medicine. It doesn’t cause allergies. The mixture is homogeneous, with a thick and stable consistency. It consists of levomenthol (Levomentol), pine oil (Pini silvestris oil), lavender oil, thyme oil (Thimi oil), eucalyptus oil (Eucalyptis oil), nutmeg oil, and excipients vetiver oil, olive oil, and vaseline.
Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid.   
Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) occur occasionally, but are usually mild and may subside with continuation of therapy. Although the absorption of iron is best when taken between meals, giving Folitin-Z TM after meals may control occasional gastrointestinal disturbances. Folitin-Z TM is best absorbed when taken at bedtime. Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein. However, allergic and idiosyncratic reactions are possible at lower levels. Iron, even at the usually recommended levels, has been associated with gastrointestinal intolerance in some patients.
Tramadol

Serious and rarely fatal anaphylactic reactions have been reported in patients receiving therapy with tramadol, a component of SEGLENTIS. When these events do occur, it is often following the first dose. Other reported allergic reactions include pruritus, hives, bronchospasm, angioedema, toxic epidermal necrolysis, and Stevens-Johnson syndrome. Patients with a history of hypersensitivity reactions to tramadol and other opioids may be at increased risk and therefore should not receive SEGLENTIS [see Contraindications (4)]. If anaphylaxis or other hypersensitivity occurs, stop administration of SEGLENTIS immediately, discontinue SEGLENTIS permanently, and do not rechallenge with any formulation of tramadol. Advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction [see Contraindications (4)].

Celecoxib

Celecoxib, a component of SEGLENTIS has been associated with anaphylactic reactions in patients with and without known hypersensitivity to celecoxib and in patients with aspirin sensitive asthma. Celecoxib is a sulfonamide and both NSAIDs and sulfonamides may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people [see Contraindications (4) and Warnings and Precautions (5.24)].

Seek emergency help if any anaphylactic reaction occurs.
The invention provides an amoxillin-potassium clavulanatein 4:1 dispersible tablet. The dispersible tablet adopts lactose, crystallite fibrin and crystal mannitol as thinner, and adopts crosslinked polyvinyl pyrrolidone (XL type) as disintegrant and also adopts micro-powder silica gel and magnesium stearate as lubricant. The dispersible tablet of the invention adopts the lactose and mannitol with better fluidity, which is good for directly pressing the powder into tablet. The invention also provides a technique of the dispersible tablet: subsidiary substances are dried for 12 to 16 hours at the temperature of 80 to 100 DEG C; the two-time tablet pressing technique is adopted and the crystallite fibrin is added both internally and externally. The environment-humidity is less than 28 percent, and the environment-temperature is below 30 DEG C in the whole preparation process. The method of the invention thoroughly dries the subsidiary substances and the process environment-humidity is controlled, so as to guarantee the stability of the product; the mixing between the subsidiary substances and the medicines, the internal and external adding method is adopted, so as to enhance the disintegrating speed of the dispersible tablet; by adopting the two-time tablet-pressing method, the dispersing equality and hardness of the dispersible tablet can be improved.